Opinion|Videos|July 2, 2024
Going Beyond Topical Steroids and Calcineurin Inhibitors for AD Treatment
The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.
Advertisement
Episodes in this series
- Based on your experience, how have topical treatments evolved beyond the use of topical steroids and topical calcineurin inhibitors?
- When it comes to topical ruxolitinib, how do you balance the efficacy versus the safety when deciding to treat patients with it?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
2
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
3
60% of US Women Face Barriers to Postpartum, Mental Health Care
4
Texas Hospitals Lose $27 Million a Day in Medicaid Funding Dispute
5